Physician profile
Mohammad Alsumrain
NPI 1639327885
$13,737.66
in general payments reported to CMS, 2019-2025
22 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2021: $84.18 · 2022: $64.28 · 2023: $457 · 2024: $529 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,277.31 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $275.12 | 2024-2025 | Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $184.58 | 2023-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $119.93 | 2019 | |
| Insmed, INC. | $110.58 | 2021-2024 | Arikayce |
| Mylan Specialty L.P. | $102.57 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $100.11 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Grifols USA, LLC | $78.79 | 2019-2022 | |
| Amgen INC. | $56.92 | 2023-2025 | Tezspire |
| Verona Pharma, INC. | $56.19 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $55.70 | 2023-2024 | Cresemba |
| Merck Sharp & Dohme LLC | $53.99 | 2024-2025 | Zerbaxa, Recarbrio, Dificid |
| United Therapeutics Corporation | $42.63 | 2023 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $39.35 | 2024-2025 | Glassia |
| Inogen, INC. | $33.10 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $29.42 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| 3b Medical, INC. | $29.04 | 2024 | Luna |
| Genzyme Corporation | $28.87 | 2024-2025 | |
| Pinnacle Biologics, INC | $24.10 | 2024 | Photofrin |
| Pulmonx Corporation | $23.93 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Electromed, INC. | $15.43 | 2023 | Smartvest |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alsumrain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.